Reporter brief
Improving Physical Ability and Cellular Senescence Elimination in HIV
What happened
Trial registry update: COMPLETED. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract reports only the protocol, not outcomes—it is unclear whether the trial found any benefit, harm, or difference between groups.
- The study is small (80 participants) and in a specific population (older people with HIV), so any findings would not necessarily apply to other populations or ages.
- A 12-week intervention period may be too short to determine durable effects on physical function or cellular senescence.
Study design and sample
Rct; Human.
People with HIV aged 50 or older who have been living with HIV for at least 10 years, meeting criteria for frail or prefrail diagnosis, and currently on stable antiretroviral therapy with viral suppression
- Design
- Rct
- Sample
- 80
- Journal
- National Institute of Allergy and Infectious Diseases (NIAID)
- Published
- Sep 15, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.